Humacyte, Inc. – NASDAQ:HUMAW
Humacyte stock price today
$0.23
-1.98
-89.59%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 21 minutes
Humacyte stock price monthly change
+1.38%
month
Humacyte stock price quarterly change
+1.38%
quarter
Humacyte stock price yearly change
+391.11%
year
Humacyte key metrics
Market Cap | 208.44M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1 |
Revenue | N/A |
EBITDA | -89.17M |
Income | -105.70M |
Revenue Q/Q | N/A |
Revenue Y/Y | 710.06% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHumacyte stock price history
Humacyte stock forecast
Humacyte financial statements
| Jun 2023 | 0 | -22.70M | |
|---|---|---|---|
| Sep 2023 | 0 | -25.99M | |
| Dec 2023 | 10.79M | -25.10M | -232.68% |
| Mar 2024 | 0 | -31.89M |
| Jun 2023 | 168106000 | 106.98M | 63.64% |
|---|---|---|---|
| Sep 2023 | 149385000 | 112.39M | 75.24% |
| Dec 2023 | 128223000 | 114.67M | 89.44% |
| Mar 2024 | 161466000 | 135.31M | 83.8% |
| Jun 2023 | -22.60M | 1.62M | 6.01M |
|---|---|---|---|
| Sep 2023 | -13.00M | -493K | -764K |
| Dec 2023 | -19.05M | -150K | -335K |
| Mar 2024 | -27.34M | -391K | 62.79M |
Humacyte alternative data
| Jan 2024 | 164 |
|---|---|
| Feb 2024 | 164 |
| Mar 2024 | 164 |
| Apr 2024 | 183 |
| May 2024 | 183 |
| Jun 2024 | 183 |
| Jul 2024 | 183 |
Humacyte other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 34525 | 0 |
| Sep 2022 | 114000 | 4567500 |
| Dec 2022 | 45000 | 2817804 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | NIKLASON LAURA E director, 10 perc.. | Stock Options (right to buy) | 100,000 | $1.19 | $119,000 | ||
Option | NIKLASON LAURA E director, 10 perc.. | Common Stock | 100,000 | $1.19 | $119,000 | ||
Option | DOUGAN BRADY W director, 10 percent owner | Stock Options (right to buy) | 100,000 | $1.19 | $119,000 | ||
Option | DOUGAN BRADY W director, 10 percent owner | Common Stock | 100,000 | $1.19 | $119,000 | ||
Purchase | SANDER DALE A. officer: CFO and Chief Corp. De.. | Common Stock | 20,000 | $2.6 | $52,000 | ||
Sale | NIKLASON LAURA E director, 10 perc.. | Common Stock | 239,538 | $2.53 | $606,031 | ||
Sale | AYABUDGE LLC 10 percent owner | Common Stock | 239,538 | $2.53 | $606,031 | ||
Sale | DOUGAN BRADY W director, 10 percent owner | Common Stock | 239,538 | $2.53 | $606,031 | ||
Purchase | NIKLASON LAURA E director, 10 perc.. | Common Stock | 10,000 | $2.54 | $25,400 | ||
Purchase | DOUGAN BRADY W director, 10 percent owner | Common Stock | 10,000 | $2.54 | $25,400 |
-
What's the price of Humacyte stock today?
One share of Humacyte stock can currently be purchased for approximately $0.23.
-
When is Humacyte's next earnings date?
Unfortunately, Humacyte's (HUMAW) next earnings date is currently unknown.
-
Does Humacyte pay dividends?
No, Humacyte does not pay dividends.
-
How much money does Humacyte make?
Humacyte has a market capitalization of 208.44M.
-
What is Humacyte's stock symbol?
Humacyte, Inc. is traded on the NASDAQ under the ticker symbol "HUMAW".
-
What is Humacyte's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Humacyte?
Shares of Humacyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Humacyte have?
As Jul 2024, Humacyte employs 183 workers.
Humacyte company profile:
Exchange:
NASDAQ
Full time employees:
183
Industry:
Biotechnology
Sector:
Healthcare
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
,
CIK: 0001818382
ISIN: US44486Q1114
CUSIP: 44486Q111
